What is the fair value of Pharma Mar SAU (OTC-PHMM.F) stock?

The current fair value estimate for Pharma Mar SAU (OTC-PHMM.F) is $93.05. This implies an estimated downside of 1.6% versus the current market price.

Is Pharma Mar SAU (OTC-PHMM.F) undervalued or overvalued?

Based on the current fair value estimate, the stock is trading close to its estimated fair value.

How is the financial health of Pharma Mar SAU?

The current financial health read for Pharma Mar SAU (OTC-PHMM.F) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

When is Pharma Mar SAU's next earnings date?

The next earnings date currently listed for Pharma Mar SAU (OTC-PHMM.F) is November 4, 2026.

Does Pharma Mar SAU (OTC-PHMM.F) pay dividends?

The latest available data indicates no current dividend yield for Pharma Mar SAU (OTC-PHMM.F).

What is the P/E ratio for Pharma Mar SAU (OTC-PHMM.F)?

The current P/E ratio listed for Pharma Mar SAU (OTC-PHMM.F) is 22.8x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

What is the market capitalization of Pharma Mar SAU?

The current market capitalization listed for Pharma Mar SAU is 1.482 B.

What is the enterprise value of Pharma Mar SAU?

The current enterprise value listed for Pharma Mar SAU is 1.323 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

What is the ticker symbol for Pharma Mar SAU?

The ticker symbol for Pharma Mar SAU is OTC-PHMM.F, and the stock is listed on OTC Markets.

Where is Pharma Mar SAU (OTC-PHMM.F) listed?

Pharma Mar SAU (OTC-PHMM.F) is listed on OTC Markets.

What is the debt-to-total-capital ratio for Pharma Mar SAU?

The current debt-to-total-capital ratio listed for Pharma Mar SAU is 3.5%, which helps investors evaluate the company’s financing structure and leverage profile.

What is the free float for Pharma Mar SAU?

The free float listed for Pharma Mar SAU is 77.3%. Free float helps investors understand how much of the share base is available for public trading.

Pharma Mar SAU (PHMMF) Fair Value & Stock Analysis

Pharma Mar SAU (PHMMF)

Pharma Mar, S.A. is a Madrid-based biopharmaceutical company focused on oncology and RNA interference. The company’s activities include research, development, production, and commercialization of bioactive compounds used in cancer care, with operations spanning Spain, several European markets, the United States, and other international regions. Its oncology portfolio includes Yondelis for soft tissue sarcoma and ovarian cancer, Zepzelca for small cell lung cancer, and Aplidin for multiple myeloma. Pharma Mar is also advancing several clinical-stage programs, including LAGOON and SaLuDo in Phase III, PM534 and PM54 in Phase I, and SYL1801 in Phase II. In addition, the company works on products designed to reduce or silence gene expression.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Fair Value Upside/Downside	Fair Value Rating	Analyst Price Target	Analyst Target Upside/Downside	Overall Financial Health	Dividend Yield	Next Earnings Date	P/E Ratio	Price-to-Book Ratio	Price-to-Sales Ratio	Market Cap	Enterprise Value	Total Debt / Total Capital	Free Float / Shares Outstanding	Altman Z-Score	Payout Ratio	Free Cash Flow / Net Income
OTC-PHMM.F	$93.05	-1.6% Downside	Fair	Not available	Not available	Great	0.0%	November 4, 2026	22.8x	5.1x	5.9x	1.482 B	1.323 B	3.5%	77.3%	10.8	0.0%	96.2%